Evaluation of Mineral and Bone Disorders in End-Stage Renal Disease Patients Undergoing Hemodialysis in Iraq: A Cross-Sectional Study at Al-Hussein Teaching Hospital, Samawah
Keywords:
Chronic kidney disease–mineral and bone disorder, End-stage renal disease, Hemodialysis, Secondary hyperparathyroidism, Hyperphosphatemia, Vitamin D deficiency, IraqAbstract
Chronic kidney disease–mineral and bone disorder CKD-MBD affects nearly all patients with end-stage renal disease (ESRD) and contributes to fractures, vascular calcification, and mortality. Data from southern Iraq remain scarce.
Objective: To evaluate the prevalence and pattern of biochemical CKD-MBD abnormalities among patients receiving maintenance hemodialysis at Al-Hussein Teaching Hospital, Samawah, and to identify factors associated with severe secondary hyperparathyroidism.
We enrolled 110 adult patients who had received maintenance hemodialysis for at least three months in a cross-sectional study. Demographic, clinical, and therapeutic characteristics were extracted from medical records and clinical assessments. Before dialysis, we measured serum calcium, phosphorus, albumin, alkaline phosphatase, iFZ, and 25-hydroxyvitamin D in the respective laboratory. We classified results according to KDIGO 2017 guidelines. Logistic regression identified factors associated with iFZ exceeding twice the upper limit.
Results: The mean age was 49.6 ± 13.8 years and 56.4% of the participants were males. Higher prevalence of patients receiving dialysis twice per week was found among 71.8% patients. The number of patients with hyperphosphatemia (> ² ² 5.5 mg/dL) was 62.7%. The episode of hypocalcemia among the patients occurred among 52.7% 55 . Calcium-phosphorus product was high among 37.3% participants. Levels of iFZbeing higher than nine times the upper level occurred among 45.5% participants while only 11.8% had their levels below two times the limit. Vitamin D deficiency (<20 ng/mL) occurred among 60.0% of the participants. Only 13.6% of the participants were successful in reaching the targets for calcium, phosphorus and iFZcompliance. The length of dialysis treatment of over five years (adjusted OR 5.62) and the presence of hyperphosphatemia (adjusted OR 3.18) were found to be independently contributing to the development of the severe form of hyperparathyroidism, whereas the effect of diabetic nephropathy proved to be negative (adjusted OR 0.38).
Conclusion: CKD-MBD is very common and poorly treated in hemodialysis patients in Samawah, characterized by hyperphosphatemia, and an advanced stage of secondary hyperparathyroidism and deficiency of vitamin D. Thus, improvements in the effectiveness of dialysis treatment, the control over phosphate intake, the implementation of standard biochemical tests, and the availability of non-calcium phosphate binders, active vitamin D, calcimimetics should be the key focus.